Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...

By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...

Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy ...

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...